News|Articles|August 6, 2024

Clearside Biomedical sets sights on suprachoroidal drug delivery

The company hosted a virtual KOL event focusing on applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on wet AMD, and ongoing SCS clinical programs.

Clearside Biomedical, Inc recently hosted a virtual key opinion leader (KOL) event focusing on applicability and real-world experience with suprachoroidal drug delivery, the suprachoroidal space (SCS) as a differentiator in the retinal treatment landscape with a focus on neovascular age-related macular degeneration (wet AMD), and ongoing SCS clinical programs, including potential future development opportunities for the company.